Emerging evidence suggests that excessive alcohol consumption is associated with psoriasis. In alcoholics, antipsoriatic treatments are less efficient, but more toxic and an additional challenge is poor therapeutic compliance. There is a correlation between excess alcohol intake and increased risk of infections, but on the other hand alcohol and its metabolites can trigger a persistent systemic inflammation, mediated by pro-inflammatory cytokines released from activated Kupffer cells in the liver and from monocytes in the circulation. Ethanol and its metabolites can also enhance lymphocyte and keratinocyte activation and proliferation and can increase the mRNA levels of genes characteristic for proliferating keratinocytes. In this review, we discuss the mechanisms by which alcohol contributes to psoriasis development focusing on liver, systemic inflammation and skin.

Keywords:
Psoriasis, Alcohol, Acetaldehyde, Acetone, Alcoholic liver disease, Systemic inflammation
1.
Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496-509.
2.
Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ: Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9:679-691.
3.
Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M: Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143.
4.
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A: Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-2183.
5.
Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD: Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998;111:1072-1078.
6.
Dika E, Bardazzi F, Balestri R, Maibach HI: Environmental factors and psoriasis. Curr Probl Dermatol 2007;35:118-135.
7.
Higgins EM, du Vivier AW: Alcohol and the skin. Alcohol Alcohol 1992;27:595-602.
8.
Higgins EM, du Vivier AW: Cutaneous disease and alcohol misuse. Br Med Bull 1994;50:85-98.
9.
Zhu KJ, Zhu CY, Fan YM: Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol 2012;39:770-773.
10.
McClain CJ, Cohen DA: Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-351.
11.
Lucey MR, Mathurin P, Morgan TR: Alcoholic hepatitis. N Engl J Med 2009;360:2758-2769.
12.
Farkas A, Kemeny L: Psoriasis and alcohol: is cutaneous ethanol one of the missing links? Br J Dermatol 2010;162:711-716.
13.
Tobin AM, Higgins EM, Norris S, Kirby B: Prevalence of psoriasis in patients with alcoholic liver disease. Clin Exp Dermatol 2009;34:698-701.
14.
Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gabele E, Isayama F, Thurman RG: Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002;168:2963-2969.
15.
Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG: Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001;34:101-108.
16.
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680.
17.
Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, Thurman RG: Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001;166:4737-4742.
18.
McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE: Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology 2005;128:2066-2076.
19.
Zhao XJ, Dong Q, Bindas J, Piganelli JD, Magill A, Reiser J, Kolls JK: TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. J Immunol 2008;181:3049-3056.
20.
Laso FJ, Iglesias MC, Lopez A, Ciudad J, San Miguel JF, Orfao A: Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol 1998;28:771-777.
21.
Gonzalez-Reimers E, Santolaria-Fernandez F, Medina-Garcia JA, Gonzalez-Perez JM, de la Vega-Prieto MJ, Medina-Vega L, Martin-Gonzalez C, Duran-Castellon MC: TH-1 and TH-2 cytokines in stable chronic alcoholics. Alcohol Alcohol 2012;47:390-396.
22.
Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS: Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
23.
Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-276.
24.
Qin L, He J, Hanes RN, Pluzarev O, Hong JS, Crews FT: Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J Neuroinflammation 2008;5:10.
25.
Gonzalez-Quintela A, Campos J, Loidi L, Quinteiro C, Perez LF, Gude F: Serum TNF-alpha levels in relation to alcohol consumption and common TNF gene polymorphisms. Alcohol 2008;42:513-518.
26.
Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL: Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259.
27.
Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, Williams R: Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993;18:41-46.
28.
Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L: Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J He-patol 2012;2012:231210.
29.
Tung KH, Huang YS, Yang KC, Perng CL, Lin HC, Lee SD: Serum interleukin-12 levels in alcoholic liver disease. J Chin Med Assoc 2010;73:67-71.
30.
Laso FJ, Iglesias MC, Lopez A, Ciudad J, San Miguel JF, Orfao A: Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol 1998;28:771-777.
31.
McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM: Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986;39:1479-1485.
32.
Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ: Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-552.
33.
Hoek JB, Pastorino JG: Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002;27:63-68.
34.
Dey A, Cederbaum AI: Alcohol and oxidative liver injury. Hepatology 2006;43:S63-S74.
35.
Wu D, Cederbaum AI: Oxidative stress and alcoholic liver disease. Semin Liver Dis 2009;29:141-154.
36.
Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Deviere J: The interleukin-17 pathway is involved in human alcoholic liver disease. He-patology 2009;49:646-657.
37.
Casey CA, Nanji A, Cederbaum AI, Adachi M, Takahashi T: Alcoholic liver disease and apoptosis. Alcohol Clin Exp Res 2001;25:49S-53S.
38.
Thurman RG, Bradford BU, Iimuro Y, Frankenberg MV, Knecht KT, Connor HD, Adachi Y, Wall C, Arteel GE, Raleigh JA, Forman DT, Mason RP: Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Front Biosci 1999;4:e42-e46..
39.
Greijer AE, van der Wall E: The role of hyp-oxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009-1014.
40.
Matzinger P: The danger model: a renewed sense of self. Science 2002;296:301-305.
41.
Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ: Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007;46:823-830.
42.
Fukui H, Brauner B, Bode JC, Bode C: Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991;12:162-169.
43.
Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A: Production of inflammatory cytokines by peripheral blood monocytes in chronic alcoholism: relationship with ethanol intake and liver disease. Cytometry B Clin Cytom 2007;72:408-415.
44.
McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S: Monocyte activation in alcoholic liver disease. Alcohol 2002;27:53-61.
45.
McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I: Recent advances in alcoholic liver disease. 4. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G497-G502.
46.
Deviere J, Content J, Denys C, Vandenbus-sche P, Schandene L, Wybran J, Dupont E: Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990;11:628-634.
47.
Schafer C, Schips I, Landig J, Bode JC, Bode C: Tumor-necrosis-factor and interleukin-6 response of peripheral blood monocytes to low concentrations of lipopolysaccharide in patients with alcoholic liver disease. Z Gastroenterol 1995;33:503-508.
48.
Tachiyama G, Sakon M, Kambayashi J, Iijima S, Tsujinaka T, Mori T: Endogenous endotoxemia in patients with liver cirrhosis - a quantitative analysis of endotoxin in portal and peripheral blood. Jpn J Surg 1988;18:403-408.
49.
Hanck C, Glatzel M, Singer MV, Rossol S: Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis. J Hepatol 2000;32:51-57.
50.
Fukui H: Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. Alcohol Clin Exp Res 2005;29:172S-179S.
51.
Tanaka S, Kumashiro R, Tanikawa K: Role of the spleen in endotoxin-induced hepatic injury in chronic alcohol-fed rats. Liver 1992;12:306-310.
52.
Muzes G, Deak G, Lang I, Gonzalez-Cabello R, Gergely P, Feher J: Depressed monocyte production of interleukin-1 and tumor necrosis factor-alpha in patients with alcoholic liver cirrhosis. Liver 1989;9:302-306.
53.
Ledesma CF, Echevarria VS, Lozano Polo JL, Oloriz RR, Alvarez MC, Pons RF: Interleukin-1 in alcoholic cirrhosis of the liver: the influence of nutrition. Eur J Clin Nutr 1992;46:527-533.
54.
Gosset P, Wallaert B, Canva-Delcambre V, Colombel JF, Tonnel AB: Impaired secretion and mRNA expression of monokines by alveolar macrophages from nonsmoking patients with alcoholic liver cirrhosis. J Infect Dis 1995;171:743-746.
55.
Le Moine O, Marchant A, De Groote D, Azar C, Goldman M, Deviere J: Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995;22:1436-1439.
56.
Hill DB, D'Souza NB, Lee EY, Burikhanov R, Deaciuc IV, de Villiers WJ: A role for interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res 2002;26:74-82.
57.
Jacobi U, Bartoll J, Sterry W, Lademann J: Orally administered ethanol: transepidermal pathways and effects on the human skin barrier. Arch Dermatol Res 2005;296:332-338.
58.
Segre JA: Epidermal barrier formation and recovery in skin disorders. J Clin Invest 2006;116:1150-1158.
59.
Brand RM, Jendrzejewski JL, Henery EM, Charron AR: A single oral dose of ethanol can alter transdermal absorption of topically applied chemicals in rats. Toxicol Sci 2006;92:349-355.
60.
Buono MJ: Sweat ethanol concentrations are highly correlated with co-existing blood values in humans. Exp Physiol 1999;84:401-404.
61.
Giles HG, Meggiorini S, Renaud GE, Thiessen JJ, Vidins EI, Compton KV, Saldivia V, Orrego H, Israel Y: Ethanol vapor above skin: determination by a gas sensor instrument and relationship with plasma concentration. Alcohol Clin Exp Res 1987;11:249-253.
62.
Farkas A, Kemeny L, Szell M, Dobozy A, Bata-Csorgo Z: Ethanol and acetone stimulate the proliferation of HaCaT keratinocytes: the possible role of alcohol in exacerbating psoriasis. Arch Dermatol Res 2003;295:56-62.
63.
Farkas A, Kemeny L: The alcohol metabolite acetaldehyde and psoriasis: another trigger factor? Clin Exp Dermatol 2010;35:923-925.
64.
Cheung C, Smith CK, Hoog JO, Hotchkiss SA: Expression and localization of human alcohol and aldehyde dehydrogenase enzymes in skin. Biochem Biophys Res Commun 1999;261:100-107.
65.
Timmons SR, Nwankwo JO, Domann FE: Acetaldehyde activates Jun/AP-1 expression and DNA binding activity in human oral keratinocytes. Oral Oncol 2002;38:281-290.
66.
Mehic D, Bakiri L, Ghannadan M, Wagner EF, Tschachler E: Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol 2005;124:212-220.
67.
Marcekova Z, Flaig MJ, Kekus M, Ruzicka T, Rupec RA: The potential role of c-Jun activation in patients with cutaneous lichen planus. Exp Dermatol 2010;19:74-80.
68.
Fuchs J, Zollner TM, Kaufmann R, Podda M: Redox-modulated pathways in inflammatory skin diseases. Free Radic Biol Med 2001;30:337-353.
69.
Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR: Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 2008;128:2606-2614.
70.
Bhatty M, Pruett SB, Swiatlo E, Nanduri B: Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol 2011;45:523-539.
71.
Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218-224.
72.
Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broet P, Emilie D: A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-1397.
73.
Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH: A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-1960.
74.
Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V: A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-260.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.